MAY 2020

Kurt Kessler joins InterAx Biotech AG as new CEO 


Villigen, May 26th, 2020 / InterAx Biotech AG is pleased to announce that Dr. Kurt Kessler has joined the company as their new Managing Director (CEO). Kurt Kessler is a Senior Executive with 30 years of international experience in the biopharmaceutical industry. 

Kurt Kessler’s professional career has been centered in the pharmaceutical industry, with expertise in portfolio strategy, clinical development, go-to-market strategy, positioning, segmentation, and promotional optimization as marketing tools. His expertise guided numerous early stage assets through clinical development to approval, launch, and commercial success. Kurt has been working with both, small pre-clinical start-ups as well as some of the largest pharmaceutical firms in the world from early discovery through full commercialization of their assets. He has been very successful in helping Life Science companies to achieve commercial success.

Experience and outlook

As a senior Principal at ZS, a global consulting firm focused on life sciences, Kurt Kessler led their relationships with several European headquartered global pharmaceutical firms. As a leader for the ZS Marketing Business Area, Kurt also led the creation of new services and worked directly with clients in a wide range of issues in the pharmaceutical industry. Kurt also served on ZS’ Management Committee for each of the past 12 years.
Before joining ZS, Kurt devoted a decade to consulting exclusively with pharmaceutical marketers, designing and conducting hundreds of engagements to develop fact-based commercial actions. For four years he also served a diverse set of clients as a management consultant with PriceWaterhouse.

Jens Gobrecht, Head of the board of Directors of InterAx Biotech says “In the name of the board of InterAx Biotech, I am tremendously pleased to have Kurt on board. We were very lucky to be able to find and engage someone with his knowledge, experience and personality, which come as a perfect fit to the future needs of InterAx for the envisioned growth phase ahead of us. Kurt will motivate and enable the young and ambitious team to further strengthen our unique technologies for advanced drug discovery, thus creating more value for our customers.”
Kurt commented that “I am extremely pleased to join InterAx at such an exciting time in their journey. The unique approach they have already built and demonstrated to improve drug discovery are a fantastic foundation to build on.”

InterAx Biotech AG

InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate selection and design for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms. For more information, please visit

Printer friendly version.